The broad activities of the Th vaccine design described here include the increase in antibody titers to inhibit entry of pathogens into the host cell, the induction of IgG isotypes that activate Fcγ receptors to recruit effector functions against viral infections, and the ability of BCG-specific CD4+ T cells to support enhanced anti-viral CD8+ T cell responses. The gene discussed is CD8A; the disease is viral infectious disease.